These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b
118 results:

  • 1. Broussoflavonol F exhibited anti-proliferative and anti-angiogenesis effects in colon cancer via modulation of the HER2-RAS-MEK-ERK pathway.
    Zhu Y; Li X; Yue GG; Lee JK; Gao S; Wang M; Wong CK; Xiao WL; Lau CB
    Phytomedicine; 2024 Dec; 135():156243. PubMed ID: 39547096
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Regorafenib and glioblastoma: a literature review of preclinical studies, molecular mechanisms and clinical effectiveness.
    Mongiardi MP; Pallini R; D'Alessandris QG; Levi A; Falchetti ML
    Expert Rev Mol Med; 2024 Apr; 26():e5. PubMed ID: 38563164
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Zinc supplementation decreased incidence of grade ≥2 hand-foot skin reaction induced by regorafenib: A phase II randomized clinical trial.
    Huang WK; Hsu HC; Yang TS; Lu CW; Pan YR; Wu CE; Chung WH; Hung SI; Yeh CN
    Eur J Cancer; 2023 Dec; 195():113286. PubMed ID: 37968194
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Machine Learning Predicts the Oxidative Stress Subtypes Provide an Innovative Insight into colorectal cancer.
    Zhong H; Yang L; Zeng Q; Chen W; Zhao H; Wu L; Qin L; Yu QQ
    Oxid Med Cell Longev; 2023; 2023():1737501. PubMed ID: 37122535
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Identification of cancer-Associated Fibroblasts in Metastatic Lymph Nodes of colorectal Carcinoma.
    Oleynikova NA; Kharlova OA; Malkov PG; Danilova ND
    Bull Exp Biol Med; 2023 Mar; 174(5):634-638. PubMed ID: 37043062
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Platelet-derived growth factor (PDGF) cross-signaling via non-corresponding receptors indicates bypassed signaling in colorectal cancer.
    Moench R; Gasser M; Nawalaniec K; Grimmig T; Ajay AK; de Souza LCR; Cao M; Luo Y; Hoegger P; Ribas CM; Ribas-Filho JM; Malafaia O; Lissner R; Hsiao LL; Waaga-Gasser AM
    Oncotarget; 2022 Oct; 13():1140-1152. PubMed ID: 36264073
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Association between germline variants and somatic mutations in colorectal cancer.
    Barfield R; Qu C; Steinfelder RS; Zeng C; Harrison TA; Brezina S; Buchanan DD; Campbell PT; Casey G; Gallinger S; Giannakis M; Gruber SB; Gsur A; Hsu L; Huyghe JR; Moreno V; Newcomb PA; Ogino S; Phipps AI; Slattery ML; Thibodeau SN; Trinh QM; Toland AE; Hudson TJ; Sun W; Zaidi SH; Peters U
    Sci Rep; 2022 Jun; 12(1):10207. PubMed ID: 35715570
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Human Colon cancer HT29 Cell Line Treatment with High-Dose LAscorbic Acid Results to Reduced Angiogenic Proteins Expression and Elevated Pro-apoptotic Proteins Expression.
    Samie KA; Dayer D; Eshkiki ZS
    Curr Mol Med; 2023; 23(5):470-478. PubMed ID: 35713135
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Phase II study of anlotinib in combination with oxaliplatin and capecitabine for patients with RAS/BRAF wild-type metastatic colorectal adenocarcinoma as the first-line therapy.
    Liu Y; Xiao Q; He J; Hu H; Du J; Zhu Y; Chen J; Liu Z; Wang J; Sun L; Xu D; Li J; Liao X; Wang J; Cai Y; Cai C; Jin Z; Wang L; Yuan Y; Ding K
    BMC Med; 2022 May; 20(1):155. PubMed ID: 35513832
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Phase I Study of Lenvatinib and Capecitabine with External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma.
    Mehta R; Frakes J; Kim J; Nixon A; Liu Y; Howard L; Martinez Jimenez ME; Carballido E; Imanirad I; Sanchez J; Dessureault S; Xie H; Felder S; Sahin I; Hoffe S; Malafa M; Kim R
    Oncologist; 2022 Aug; 27(8):621-e617. PubMed ID: 35325225
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. The dual role of microRNA-9 in gastrointestinal cancers: oncomiR or tumor suppressor?
    Bahrami A; Jafari A; Ferns GA
    Biomed Pharmacother; 2022 Jan; 145():112394. PubMed ID: 34781141
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Donafenib: First Approval.
    Keam SJ; Duggan S
    Drugs; 2021 Nov; 81(16):1915-1920. PubMed ID: 34591285
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Microenvironmental markers are correlated with lymph node metastasis in invasive submucosal colorectal cancer.
    Sugai T; Yamada N; Osakabe M; Hashimoto M; Uesugi N; Eizuka M; Tanaka Y; Sugimoto R; Yanagawa N; Matsumoto T
    Histopathology; 2021 Oct; 79(4):584-598. PubMed ID: 33884652
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Dysregulated pdgfr alpha expression and novel somatic mutations in colorectal cancer: association to RAS wild type status and tumor size.
    Ben Jemii N; Tounsi-Kettiti H; Yaiche H; Mezghanni N; Jaballah Gabteni A; Fehri E; Ben Fayala C; Abdelhak S; Boubaker S
    J Transl Med; 2020 Nov; 18(1):440. PubMed ID: 33213472
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5
    Feng H; Liu K; Shen X; Liang J; Wang C; Qiu W; Cheng X; Zhao R
    Cell Death Dis; 2020 Oct; 11(10):916. PubMed ID: 33099574
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Nintedanib plus mFOLFOX6 as second-line treatment of metastatic, chemorefractory colorectal cancer: The randomised, placebo-controlled, phase II TRICC-C study (AIO-KRK-0111).
    Ettrich TJ; Perkhofer L; Decker T; Hofheinz RD; Heinemann V; Hoffmann T; Hebart HF; Herrmann T; Hannig CV; Büchner-Steudel P; Güthle M; Hermann PC; Berger AW; Seufferlein T
    Int J Cancer; 2021 Mar; 148(6):1428-1437. PubMed ID: 32930387
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. A prospective multicenter phase II study on the efficacy and safety of dasatinib in the treatment of metastatic gastrointestinal stromal tumors failed by imatinib and sunitinib and analysis of NGS in peripheral blood.
    Zhou Y; Zhang X; Wu X; Zhou Y; Zhang B; Liu X; Wu X; Li Y; Shen L; Li J
    Cancer Med; 2020 Sep; 9(17):6225-6233. PubMed ID: 32677196
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Development of a precision medicine pipeline to identify personalized treatments for colorectal cancer.
    Altunel E; Roghani RS; Chen KY; Kim SY; McCall S; Ware KE; Shen X; Somarelli JA; Hsu DS
    BMC Cancer; 2020 Jun; 20(1):592. PubMed ID: 32580713
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. PAI1 is a Marker of Bad Prognosis in Rectal cancer but Predicts a Better Response to Treatment with PIM Inhibitor AZD1208.
    Muñoz-Galván S; Rivero M; Peinado-Serrano J; Martinez-Pérez J; Fernández-Fernández MC; Ortiz MJ; García-Heredia JM; Carnero A
    Cells; 2020 Apr; 9(5):. PubMed ID: 32344898
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A phase I study investigation of metabolism, and disposition of [
    Liu Y; Liu L; Liu L; Wang T; Guo L; Wang Y; Gao Z; Shu Y
    Cancer Chemother Pharmacol; 2020 May; 85(5):907-915. PubMed ID: 32266457
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 6.